122 related articles for article (PubMed ID: 3782958)
1. Clinical significance of statistical discrimination employing serum TA-4, TPA, and CEA levels in uterine cervical cancer.
Yabushita H; Ogawa A; Masuda T; Noguchi M; Nakanishi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Oct; 38(10):1770-6. PubMed ID: 3782958
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
[TBL] [Abstract][Full Text] [Related]
3. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
[TBL] [Abstract][Full Text] [Related]
4. [Clinical usefulness of serum TPA, IAP and CEA levels in gynecological cancer].
Saitoh S; Nakanishi A; Noda T; Ando Y; Kamamoto Y; Moriyama I; Ichijo M
Nihon Gan Chiryo Gakkai Shi; 1984 Aug; 19(7):1496-504. PubMed ID: 6520506
[No Abstract] [Full Text] [Related]
5. Clinical significance of different serum tumor markers in gynecological malignancies.
Paulick R; Caffier H; Horner G; Lang K; Filbry E
Cancer Detect Prev; 1985; 8(1-2):115-20. PubMed ID: 4064031
[TBL] [Abstract][Full Text] [Related]
6. [A comparative evaluation of tumor markers (TPA and CEA) in various malignant neoplasms at an advanced stage].
Meregalli M; Antoniazzi V; Torchio G; Colombo E; Bocchi M; Sonzini E; Lino S
Minerva Med; 1989 Apr; 80(4):345-7. PubMed ID: 2725935
[TBL] [Abstract][Full Text] [Related]
7. Human tissue polypeptide antigen in breast cancer.
Nemoto T; Constantine R; Chu TM
J Natl Cancer Inst; 1979 Dec; 63(6):1347-50. PubMed ID: 292806
[TBL] [Abstract][Full Text] [Related]
8. [A clinical study on multiple tumor markers following therapy in patients with uterine cervical carcinoma].
Hiura M; Yorishima M; Tanaka M; Yokoyama T; Myoga H; Chiba T; Nakanishi Y
Nihon Sanka Fujinka Gakkai Zasshi; 1990 May; 42(5):471-8. PubMed ID: 2373919
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, and squamous cell carcinoma antigen in the detection of cervical cancers.
Lam CP; Yuan CC; Jeng FS; Tsai LC; Yeh SH; Ng HT
Zhonghua Yi Xue Za Zhi (Taipei); 1992 Jul; 50(1):7-13. PubMed ID: 1326391
[TBL] [Abstract][Full Text] [Related]
10. [Prediction of the recurrence of squamous cell carcinoma of the uterine cervix by monitoring serum TA-4].
Oishi T; Maruo T; Yamasaki M; Mochizuki M
Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):799-806. PubMed ID: 3598275
[TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of tumor markers in breast cancer patients].
Ito T; Tanaka S; Ban K; Sakai N; Oshita H; Oiwa T; Kanno A; Kashizuka T
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix.
Volgger B; Aspisirengil C; Genser-Krimbacher E; Ciresa-Koenig A; Daxenbichler G; Fuchs D; Windbichler G; Marth C
Cancer Lett; 2008 Apr; 262(2):183-9. PubMed ID: 18226853
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer].
Tozuka K; Yonese Y; Nakagami Y; Minowa T; Hiraoka Y; Yamada N; Hikima N; Ishii Y; Tannowa K; Fujioka Y
Gan To Kagaku Ryoho; 1984 May; 11(5):1078-83. PubMed ID: 6721513
[TBL] [Abstract][Full Text] [Related]
16. Differential immunocytochemical localization of tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) in breast cancer.
Björklund V; Björklund B
Cancer Detect Prev; 1983; 6(1-2):193-8. PubMed ID: 6883380
[TBL] [Abstract][Full Text] [Related]
17. [A study on tumor marker of tissue-polypeptide-antigen (TPA) in gynecologic malignancies].
Nakajima H; Hirata T; Norisugi T; Furuno K; Ikehata N; Utsunomiya A; Kobayashi K; Negishi Y; Akiya K
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Oct; 36(10):1877-83. PubMed ID: 6094688
[TBL] [Abstract][Full Text] [Related]
18. Combined use of carcinoembryonic antigen and tissue polypeptide antigen in oncologic therapy and surveillance.
Lüthgens M; Schlegel G
Cancer Detect Prev; 1983; 6(1-2):51-9. PubMed ID: 6883393
[TBL] [Abstract][Full Text] [Related]
19. [Importance of the tissue polypeptide antigen level in neoplastic patients. Its correlation with other tumor markers].
Ruibal A; Durán P; Lafuerza A; Bodi R; Solé LA; Rubio D; Ibarz L; De Torres JA; Domenech-Torné FM; Salvador L
Rev Esp Oncol; 1984; 31(3):409-14. PubMed ID: 6546169
[TBL] [Abstract][Full Text] [Related]
20. [Tumor markers of pancreatic cancer].
Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
